Company Standard BioTools Inc.

Equities

LAB

US34385P1084

Advanced Medical Equipment & Technology

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Standard BioTools Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
2.52 ^USD	-0.79%		-9.68%	+14.03%

Apr. 16	TD Cowen Starts Standard BioTools With Buy Rating, $3.50 Price Target	MT
Apr. 08	Standard BioTools Inc. Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the Boundaries of Tissue Imaging	CI

Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. The Company's segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The Company provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company also provides differentiated multi-omics tools for research.

Number of employees: 537

USD in Million	2022	Weight	2023	Weight	Delta
Consumables 39.3 %	47	47.8 %	42	39.3 %	-10.80%
Instruments 35.2 %	26	26.2 %	37	35.2 %	+45.96%
Service 24.4 %	24	24.2 %	26	24.4 %	+9.56%
Other 1.1 %	-	-	1	1.1 %	-

USD in Million	2022	Weight	2023	Weight	Delta
United States 41.5 %	41	41.9 %	44	41.5 %	+7.56%
EMEA 34.0 %	33	33.8 %	36	34.0 %	+9.25%
China 14.9 %	11	11.5 %	16	14.9 %	+39.82%
Asia-Pacific 7.7 %	10	9.7 %	8	7.7 %	-14.55%
Americas 2.0 %	3	3.0 %	2	2.0 %	-29.71%

Managers	Title	Age	Since
Michael Egholm CEO	Chief Executive Officer	61	22-04-03
Jeffrey Black DFI	Director of Finance/CFO	55	23-05-14
Shane Bowen CTO	Chief Tech/Sci/R&D Officer	-	Jan. 04
Hanjoon Kim COO	Chief Operating Officer	53	22-04-03
Jeremy Davis PRN	Corporate Officer/Principal	-	22-06-11
Adam Taich PRN	Corporate Officer/Principal	49	Jan. 04
Elizabeth R. Jensen HRO	Human Resources Officer	50	23-01-02
Katherine J. Flagg PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Frank R. Witney Witney BRD	Director/Board Member	70	22-03-31
Fenel Eloi BRD	Director/Board Member	66	23-03-14
Kathy Hibbs BRD	Director/Board Member	60	Jan. 04
Michael Egholm CEO	Chief Executive Officer	61	22-04-03
Eli Casdin BRD	Director/Board Member	51	22-04-03
Troy Cox BRD	Director/Board Member	60	Jan. 04
Thomas Carey CHM	Chairman	62	Jan. 04

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	293,249,930	287,216,751 ( 97.94 %)	3,132,000 ( 1.068 %)	97.94 %

Name	Equities	%	Valuation
Casdin Capital LLC 21.34 %	61,907,605	21.34 %	168 M $
Viking Global Investors LP 20.22 %	58,651,170	20.22 %	159 M $
Millennium Management LLC 5.183 %	15,037,065	5.183 %	41 M $
C-LSH LLC 2.602 %	7,548,000	2.602 %	20 M $
Indaba Capital Management LP 2.567 %	7,446,229	2.567 %	20 M $
Caligan Partners LP 2.427 %	7,042,413	2.427 %	19 M $
Caligan Partners LP 2.427 %	7,042,413	2.427 %	19 M $
Neuberger Berman Investment Advisers LLC 1.511 %	4,382,584	1.511 %	12 M $
LB Hercules Holdings LLC 1.505 %	4,365,813	1.505 %	12 M $
Vanguard Global Advisers LLC 1.425 %	4,133,939	1.425 %	11 M $

Name	Equities	%	Valuation
Viking Global Investors LP 0.0731 %	57,529	0.0731 %	155 904 $

Name	Equities	%	Valuation
Casdin Capital LLC 0.000000 %	0	0.000000 %	- $

Standard BioTools, Inc.

2 Tower Place Suite 2000

94080, South San Francisco

+650 266 6000

http://www.standardbio.com

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.54 USD

Average target price

3.583 USD

Spread / Average Target

+41.08%

Consensus

Estimates Revisions

Company calendar

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Advanced Medical Equipment & Technology

Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
STANDARD BIOTOOLS INC.	+14.03%	971M
THERMO FISHER SCIENTIFIC	+2.64%	207B
DANAHER CORPORATION	+1.80%	175B
INTUITIVE SURGICAL, INC.	+8.59%	132B
BOSTON SCIENTIFIC CORPORATION	+16.47%	99.1B
SIEMENS HEALTHINEERS AG	-3.42%	60.89B
EDWARDS LIFESCIENCES CORPORATION	+12.71%	52.04B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-6.61%	45.48B
AGILENT TECHNOLOGIES, INC.	-4.53%	38.81B
GE HEALTHCARE TECHNOLOGIES INC.	+9.27%	38.77B

Other Advanced Medical Equipment & Technology